The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Clinical Impact of Delaying Initiation of Adjuvant Chemotherapy in Patients With Breast Cancer
Open accessAbstract
Purpose: For patients with breast cancer (BC), the optimal time to initiation of adjuvant chemotherapy (TTC) after definitive surgery is unknown. We evaluated the association between TTC and survival according to breast cancer subtype and stage at diagnosis. Patients and Methods: Women diagnosed with BC stages I to III between 1997 and 2011 who received adjuvant chemotherapy at our institution were included. Patients were categorized into three groups according to TTC: ≤ 30, 31 to 60, and ≥ 61 days. Survival outcomes were estimated and compared according to TTC and by BC subtype. Results: Among the 6,827 patients included, the 5-year overall survival (OS), relapse-free survival (RFS), and distant RFS (DRFS) estimates were similar for the different TTC categories. Initiation of chemotherapy ≥ 61 days after surgery was associated with adverse outcomes among patients with stage II (DRFS: hazard ratio [HR], 1.20; 95% CI, 1.02 to 1.43) and stage III (OS: HR, 1.76; 95% CI, 1.26 to 2.46; RFS: HR, 1.34; 95% CI, 1.01 to 1.76; and DRFS: HR, 1.36; 95% CI, 1.02 to 1.80) BC. Patients with triple-negative BC (TNBC) tumors and those with human epidermal growth factor receptor 2 (HER2) –positive tumors treated with trastuzumab who started chemotherapy ≥ 61 days after surgery had worse survival (HR, 1.54; 95% CI, 1.09 to 2.18 and HR, 3.09; 95% CI, 1.49 to 6.39, respectively) compared with those who initiated treatment in the first 30 days after surgery. Conclusion: TTC influenced survival outcomes in the overall study cohort. This finding was particularly meaningful for patients with stage III BC, TNBC, and trastuzumab-treated HER2-positive tumors who experienced worse outcomes when chemotherapy was delayed. Our findings suggest that early initiation of chemotherapy should be granted for patients in these high-risk groups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra1001389 · Cited by 4,157
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910383 · Cited by 2,775
Self-citationGoss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
Joensuu, H., Kellokumpu-Lehtinen, P.-L., Bono, P., Alanko, T., Kataja, V., Asola, R., Utriainen, T., Kokko, R., Hemminki, A., Tarkkanen, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053028 · Cited by 1,403
DQIS Research Group (2026) · PubMed · doi:10.5281/zenodo.21937949 · Cited by 1,327
7th Edition of the AJCC Cancer Staging Manual: Stomach
Washington, K. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1362-z · Cited by 979
Berry, D. A., Cirrincione, C., Henderson, I. C., Citron, M. L., Budman, D. R., Goldstein, L. J., Martino, S., Perez, E. A., Muss, H. B., Norton, L., et al. (2006) · JAMA · doi:10.1001/jama.295.14.1658 · Cited by 731
Paik, S., Hazan, R., Fisher, E. R., Sass, R. E., Fisher, B., Redmond, C., Schlessinger, J., Lippman, M. E., & King, C. R. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.1.103 · Cited by 594
HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
Pritchard, K. I., Shepherd, L. E., O'Malley, F. P., Andrulis, I. L., Tu, D., Bramwell, V. H., & Levine, M. N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054504 · Cited by 509
Recht, A., Come, S. E., Henderson, I. C., Gelman, R. S., Silver, B., Hayes, D. F., Shulman, L. N., & Harris, J. R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605233342102 · Cited by 436
Effect of surgical removal on the growth and kinetics of residual tumor.
Gündüz, N., Fisher, B., & Saffer, E. (1979) · PubMed · Cited by 410
Lohrisch, C., Paltiel, C., Gelmon, K., Speers, C., Taylor, S., Barnett, J., & Olivotto, I. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.6089 · Cited by 373
Presence of a growth-stimulating factor in serum following primary tumor removal in mice.
Fisher, B., Gündüz, N., Coyle, J., Rudock, C., & Saffer, E. (1989) · PubMed · Cited by 361
Colleoni, M., Viale, G., Zahrieh, D., Pruneri, G., Gentilini, O., Veronesi, P., Gelber, R. D., Curigliano, G., Torrisi, R., Luini, A., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0380 · Cited by 353
The epidemiology of triple-negative breast cancer, including race
Trivers, K. F., Lund, M. J., Porter, P. L., Liff, J. M., Flagg, E. W., Coates, R. J., & Eley, J. W. (2009) · Cancer Causes & Control · doi:10.1007/s10552-009-9331-1 · Cited by 332
Rosen, P. P., Groshen, S., Kinne, D. W., & Norton, L. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.11.2090 · Cited by 295
McLaughlin, J. M., Anderson, R. T., Ferketich, A. K., Seiber, E. E., Balkrishnan, R., & Paskett, E. D. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.39.7695 · Cited by 213
Colleoni, M., Bonetti, M., Coates, A. S., Castiglione-Gertsch, M., Gelber, R. D., Price, K., Rudenstam, C.-M., Lindtner, J., Collins, J., Thürlimann, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.584 · Cited by 197
Bellon, J. R., Come, S. E., Gelman, R. S., Henderson, I. C., Shulman, L. N., Silver, B. J., Harris, J. R., & Recht, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.032 · Cited by 188
DAVIES, C. (2004) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(04)00121-5 · Cited by 170
The process of metastasisation for breast cancer
Engel, J., Eckel, R., Kerr, J., Schmidt, M. K., Fürstenberger, G., Richter, R., Sauer, H., Senn, H.-J., & Hölzel, D. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00422-2 · Cited by 162
Preoperative Delays in the US Medicare Population With Breast Cancer
Bleicher, R. J., Ruth, K. J., Sigurdson, E. R., Ross, E. A., Wong, Y., Patel, S. A., Boraas, M. C., Topham, N. S., & Egleston, B. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.7972 · Cited by 149
Chia, S., Speers, C. H., Bryce, C. J., Hayes, M. M., & Olivotto, I. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.070 · Cited by 144
Cold, S., Düring, M., Ewertz, M., Knoop, A. S., & Möller, S. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602734 · Cited by 129
Folkman, J. (1990) · Cancer and Metastasis Reviews · doi:10.1007/bf00046358 · Cited by 124
Even Low-level HER2 Expression May be Associated With Worse Outcome in Node-positive Breast Cancer
Gilcrease, M. Z., Woodward, W. A., Nicolas, M. M., Corley, L. J., Fuller, G. N., Esteva, F. J., Tucker, S. L., & Buchholz, T. A. (2009) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31819437f9 · Cited by 115
Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer
Buzdar, A. U., Smith, T. L., Powell, K. C., et al. (1982) · Breast Cancer Research and Treatment · doi:10.1007/bf01806452 · Cited by 91
Sánchez, C. J., Ruı́z, A., Martín, M., Antón, A., Munárriz, B., Plazaola, A., Schneider, J., del Prado, P. M., Alba, E., & Fernández, A. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9282-0 · Cited by 58
Cited by
Mortality due to cancer treatment delay: systematic review and meta-analysis
Hanna, T. P., King, W. D., Thibodeau, S., Jalink, M., Paulin, G. A., Harvey-Jones, E., O’Sullivan, D. E., Booth, C. M., Sullivan, R., & Aggarwal, A. (2020) · BMJ · doi:10.1136/bmj.m4087 · Cited by 1,742
Cancer progression and the invisible phase of metastatic colonization
Klein, C. A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-00300-6 · Cited by 375
Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer
Chavez-MacGregor, M., Clarke, C. A., Lichtensztajn, D. Y., & Giordano, S. H. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.3856 · Cited by 370
Self-citationDetecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease
Moding, E. J., Nabet, B. Y., Alizadeh, A. A., & Diehn, M. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0634 · Cited by 325
The obesity paradox in cancer-moving beyond BMI
Strulov Shachar, S., & Williams, G. R. (2017) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0439 · Cited by 198
Metadata
- Authors
- Gagliato, D. D. M., Gonzalez-Angulo, A. M., Lei, X., Theriault, R. L., Giordano, S. H., Valero, V., Hortobagyi, G. N., & Chavez-MacGregor, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-03-10
- Volume
- 32
- Issue
- 8
- Pages
- 735-744
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2102717344
- Cited by
- 279
- References
- 34
- FWCI
- 8.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.